logo
logo
AI Products 

Cannabinoids Are Fastest Growing Segment Fueling The Growth Of Prochlorperazine Maleate Market

avatar
Mia Yates
Cannabinoids Are Fastest Growing Segment Fueling The Growth Of Prochlorperazine Maleate Market

The global Prochlorperazine Maleate Market is estimated to be valued at US$ 1.46 Bn in 2023 and is expected to exhibit a CAGR of 3.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.


Market Overview:

Prochlorperazine maleate is commonly used to treat nausea and vomiting. It works by blocking certain chemicals in the brain that trigger vomiting. Prochlorperazine maleate is also used to treat psychotic disorders like schizophrenia. It helps in relieving psychotic symptoms like hallucinations and delusions.


Market key trends:

One of the key trends in the Prochlorperazine Maleate Market is the growing adoption of cannabinoids for treating nausea and vomiting. Cannabinoids present in cannabis and hemp plants are being widely researched for their antiemetic properties. They work by interacting with receptors in the brain and gastrointestinal tract to reduce nausea and vomiting. Cannabinoids are emerging as an alternative to traditional antiemetic drugs like Prochlorperazine. Research studies indicate cannabinoids are equally effective in controlling chemotherapy-induced nausea and vomiting. Their non-addictive nature makes them an attractive option. This growing acceptance of cannabinoids is expected to hamper the growth of Prochlorperazine Maleate Market over the forecast period.


Segment Analysis

The global prochlorperazine maleate market is dominated by the oral segment. This is owing to the ease of administration and high patient compliance associated with oral drugs. Furthermore, oral drugs eliminate risks associated with other modes of administration such as injections.


Key Takeaways

The global Prochlorperazine Maleate Market Size is expected to witness high growth, exhibiting CAGR of 3.5% over the forecast period, due to increasing prevalence of schizophrenia and other psychotic disorders.


Regional analysis

North America is expected to dominate the global prochlorperazine maleate market over the forecast period due to rising adoption of novel drugs and growing cases of migraine headaches and psychotic disorders in the region.


Key players

Key players operating in the prochlorperazine maleate market are GlaxoSmithKline plc, Pfizer Inc., Novartis AG, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., Johnson & Johnson, AbbVie Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Lupin Limited.


Read More: https://www.ukwebwire.com/prochlorperazine-maleate-market-size-share-and-growth-forecast/

collect
0
avatar
Mia Yates
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more